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Influence of long-term treatment with equine somatotropin 
(EquiGen®) on gonadal function in stallions with poor semen quality 
 
D. De Bottona, F. Janettb, D. Burgera, I. Imbodena, W. Kähnb, R. Thunb 
aNational Stud, Avenches, Switzerland 
bClinic of Reproduction, University of Zürich, Switzerland 
 
1. Summary 
The aim of the present study was to investigate the spermatogenic and Leydig cell 
activity in stallions with impaired semen quality after treatment with equine 
somatotropin. Experiments were performed using 18 adult clinically healthy stallions 
with poor semen quality which did not pass breeding soundness evaluation. The 
animals were randomly divided into a treatment (n=9) and a control (n=9) group. 
Over a period of 90 days, nine stallions received a daily intramuscular injection of 10 
mg recombinant equine somatotropin (EquiGen®, BresaGen Limited, Adelaide, 
Australia) and 9 control animals were injected with the same amount of physiological 
saline solution. During and until 2 months after treatment, semen characteristics and 
daily sperm output as well as plasma testosterone concentrations were determined 
monthly in all stallions. In addition, testosterone concentration measurement after 
stimulation with hCG was performed in all animals immediately before and at the end 
of the treatment period as well as 2 months later. Our results demonstrate that 
equine somatotropin (EquiGen®) given daily in a dose of 10 mg per animal during 90 
days had no significant effect neither on plasma testosterone concentrations and 
hCG-induced testosterone release nor on semen quality parameters in adult stallions 
with poor semen characteristics. 
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2. Zusammenfassung 
 
Einfluss einer Langzeitbehandlung mit equinem Somatotropin (EquiGen®) auf 
die Hodenfunktion von Hengsten mit schlechter Samenqualität 
 
Ziel der vorliegenden Arbeit war es, die Wirkung von equinem Somatotropin auf die 
Spermatogenese und Leydig-Zell Aktivität bei Hengsten mir reduzierter 
Samenqualität abzuklären. Für die Untersuchungen standen 18 adulte, klinisch 
gesunde Hengste vom Nationalgestüt in Avenches zur Verfügung, welche aufgrund 
ungenügender Samenqualität als nicht zuchttauglich eingestuft worden waren. Die 
Tiere wurden zufällig einer Behandlungs- (n=9) und Kontrollgruppe (n=9) 
zugewiesen. Neun Hengste erhielten täglich, während einer Dauer von 90 Tagen, 10 
mg recombinantes equines Somatotropin (EquiGen®, BresaGen Limited, Adelaide, 
Australia) i.m. injiziert während den 9 Kontrolltieren die entsprechende Menge 
physiologische Kochsalzlösung verabreicht wurde. Während und bis 2 Monaten nach 
Ende der Behandlung wurde monatlich bei allen Hengsten die Samenqualität 
beurteilt sowie die tägliche Spermienproduktion und die Plasmakonzentration von 
Testosteron bestimmt. Zusätzlich wurde bei allen Tieren unmittelbar vor und nach 
Ende der Behandlung sowie 2 Monate später eine Stimulation mit hCG 
vorgenommen. Aufgrund unserer Ergebnisse kann gefolgert werden, dass die 
tägliche Verabreichung von 10 mg equinem Somatotropin (EquiGen®) während 90 
Tagen weder die Samenqualität noch die Plasmakonzentrationen von Testosteron 
ohne und nach hCG-Stimulation bei Hengsten mit schlechter Samenqualität 
signifikant beeinflusst hat. 
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3. Résumé 
 
Influence de la somatotropine équine recombinante (EquiGen®) sur la qualité 
de la semence et la sécrétion de testostérone chez l’étalon 
 
Chez l’étalon, l’influence de l’hormone de croissance sur la régulation des fonctions 
reproductives est encore peu connue. Le but de cette étude était d’examiner l’activité 
des cellules germinales et de Leydig chez l’étalon après un traitement avec de la 
somatotropine équine. L’expérience a été effectuée sur 18 étalons du Haras National 
d’Avenches qui n’ont pas passé l’examen de la fonction génitale a cause d’une 
mauvaise qualité de la semence. Les animaux ont été répartis au hasard en un 
groupe de traitement (n=9) et un groupe de contrôle (n=9). Pendant une période de 
90 jours, neuf étalons ont reçu une injection intramusculaire quotidienne de 10 mg de 
somatotropine équine recombinante (EquiGen®, BresaGen Limited, Adelaide, 
Australie) alors que les neuf animaux de contrôle ont reçu, de manière similaire, la 
même quantité d’une solution physiologique saline. Pendant et jusqu’à 2 mois après 
le traitement, la qualité de la semence et le nombre total de spermatozoïdes produit 
par jour, ainsi que la concentration de testostérone plasmatique ont été déterminés 
chez tous les étalons. De plus, des mesures de la concentration de testostérone 
après stimulation à l’hCG ont été effectuées chez tous les animaux immédiatement 
avant et à la fin de la période de traitement, ainsi que 2 mois plus tard. Nos résultats 
démontrent que l’administration de somatotropine équine recombinante n’a d’effets 
significatifs ni sur les caractéristiques qualitatives de la semence, ni sur la 
concentration de testostérone plasmatique et sur la sécrétion de testostérone induite 
par le test hCG. 
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4. Introduction 
Somatotropin (ST) is a growth hormone (GH) released by the anterior pituitary gland 
that is essential for normal skeletal development. In recent years, accumulated 
clinical and laboratory evidence suggests that ST also plays an important role in the 
reproductive system by influencing gonadal development in young animals and 
maintaining normal reproductive function in adult animals. GH receptors have not 
only been detected in the ovary of various species (Mathews et al., 1989; Lobie et al., 
1990; Schams and Berisha, 2004) but also in the male reproductive system including 
Leydig and Sertoli cells, the vas deferens, the prostate gland, the ductus epididymis 
and the seminal vesicles (Lobie et al., 1990; N’Diaye et al., 2002). Moreover, delayed 
puberty has been observed in human patients with GH deficiency or GH resistance, 
and subjects with GH excess as in acromegaly have been known to be infertile 
(Codner and Cassorla, 2002). Early studies on rats indicated an apparent association 
of GH-deficiency with both compromised spermatogenesis and impaired sperm 
motility (Breier et al., 1996; Gravance et al., 1997). Furthermore, treatment of 
subfertile male GH-deficient rats with recombinant bovine GH, markedly increased 
sperm motility as well as plasma concentration of insulin-like growth factor-I (IGF-I). 
IGF-I is synthesized in the liver as well as in the gonads and is directly stimulated by 
GH (Breier et al., 1996). A recent review (Chandrashekar et al., 2004) reports the 
presence of IGF-I receptors in the gonads of both male and female, providing further 
evidence of GH influence on gonadal activity. Finally in clinical trials in subfertile men, 
sperm motility during GH treatment was significantly increased (Ovesen et al., 1996) 
whereas in another study GH therapy had no effect in men with idiopathic 
oligozoospermia (Lee et al., 1995). 
Experimental use of GH in order to increase gonadal function has provided promising 
results in both female and male animals. In the cow, treatment with recombinant 
bovine somatotropin (bST) has been shown not only to improve oocyte morphology 
(Roth et al., 2002) but also to enhance fertility in artificially inseminated cows (Santos 
et al., 2004). Furthermore, the application of bST increased the percentage of 
transferable embryos in superovulated cows and improved pregnancy rates after 
embryo transfer (Moreira et al., 2002). In the mature bull, treatment with bST 
increased the ejaculate volume (Bousquet et al., 2004), sperm motility after 
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freezing/thawing and the non-return rate after artificial insemination (Sauerwein et al., 
2000). 
Studies concerning the use of GH in the equine species have shown controversial 
results. Similarly to GH treatment in the cow, administration of equine somatotropin 
(eST) to cyclic mares significantly increased the number of small follicles on the 
ovaries (Cochran et al., 1999). In the stallion, treatment with the somatostatin 
analogue octreotid resulted in a transient decrease in semen motility and 
testosterone release after hCG-stimulation (Aurich et al., 2003). Storer et al. (2005) 
reported that daily administration of recombinant equine GH at 20µg/kg body weight 
over 21 days increased plasma IGF-I concentrations but had no effect on blood LH, 
FSH and testosterone concentrations. GH-treated stallions showed higher ejaculate 
volume, but motility, total sperm and sperm morphology in ejaculates collected 2 
months after initiation of the GH treatment were not affected. Nonetheless higher 
pregnancy rates were observed in mares when bred with stallions showing greater 
concentrations of IGF-I in seminal plasma, suggesting a positive IGF-I effect on 
sperm function (Macpherson et al., 2002). 
The aim of the present study was to investigate the spermatogenic and Leydig cell 
activity in adult stallions with poor semen quality after long-term treatment with 
recombinant equine somatotropin. 
 
5. Material and methods 
5.1. Animals 
The experiment was carried out using 18 adult clinically healthy warmblood stallions, 
aged between 7 and 24 years from the National Stud in Avenches (Switzerland). 
From earlier studies (Janett et al., 2003a; 2003b; 2005) all stallions were known to 
have poor semen quality and did not pass semen evaluation according to the 
guidelines of “Clinical Fertility Evaluation of the Stallion” by the Society for 
Theriogenology (Kenney et al., 1983). The animals were kept in box stalls bedded 
with straw and were fed hay or haylage, oats, barley, corn and pellets supplemented 
with minerals. Water was available at libitum. All animals were exercised daily for at 
least 1 hour. 
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5.2. Experimental design 
Before the onset of the experiment, the stallions were trained to mount the phantom 
and randomly allocated to a GH treatment (n=9) and a control group (n=9) with 
similar age distribution. GH treated animals were given 10 mg per day (≈ 20 µg/kg 
body weight) of recombinant equine somatotropin (EquiGen®, BresaGen Ltd., 
Adelaide, Australia) dissolved in 2 ml sterile water for injection and the control 
animals received an equivalent volume of saline solution. In both groups daily 
injections were applied intramuscularly during a period of 90 days starting in the 
month of July. During treatment the stallions were regularly examined by a 
veterinarian and adverse reactions caused by the injections were observed and 
registered. 
 
5.3. Semen collection and examination 
Immediately before, during and until 2 months after the treatment, ejaculates were 
collected at monthly intervals, for 7 consecutive days each time from July to 
December. Semen was evaluated on days 5, 6 and 7 of each monthly collection. 
Ejaculate volume of the gel-free semen was measured with a graduated cylinder. 
Total and progressive motility, sperm concentration and total sperm were assessed in 
freshly diluted (INRA 96, IMV, Aîgle, France) semen with a Sperm Analyzer (HTM-
IVOS, Version 12, Beverly, MA, USA) using 20 micron standard count analysis 
chambers (Art. no. SC 20-01-C, Leja, Nieuw-Vennep, The Netherlands) and 
standardized threshold values for stallion semen. The monthly values for each semen 
parameter were calculated as mean of the collection days 5-7. The daily sperm 
output (DSA) was determined as mean of the total sperm from days 5-7 (Love et al., 
1991). For morphological examination, five drops of fresh semen collected on day 6 
were fixed in 2 mL Hancock solution and smears prepared. At least 200 spermatozoa 
were subsequently evaluated by phase contrast microscopy (Olympus BX50, 
UplanF1 100x/1.30) and abnormal spermatozoa classified in major (acrosome 
defects, nuclear vacuoles, abnormal heads, loose abnormal heads, abnormal 
midpieces, proximal droplets) and minor (loose normal heads, abnormal tails, distal 
droplets) defects (Blom, 1973; Jasko et al., 1990). 
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5.4. Testosterone analysis and hCG-stimulation 
Blood samples (EDTA) for testosterone determination were collected monthly on day 
7 of semen collection, between 8 and 9 am, by jugular venipuncture. In addition, an 
hCG-stimulation was performed according to Cox (1989) on all stallions, before and 
at the end of the treatment period as well as 2 months later. Immediately after 
drawing the first blood sample, 6000 IU hCG (Chorulon®, Veterinaria AG, Zürich) 
were injected intravenously and 4 further blood samples were collected at intervals of 
15 min. After collection the blood was centrifuged immediately (3000 x g, 10 min) and 
plasma decanted and stored at -80°C until testosterone analysis. Testosterone was 
determined by electrochemiluminescence immunoassay (Elecsys 2010, Roche 
Diagnostics, Basel, Switzerland) as described earlier (Wang et al., 2004). The 
detection limit of the assay was 0.02 ng/mL. All samples were analyzed using a 
biotinylated monoclonal antibody against testosterone. Cross-reactivity with 
estrogens and progesterone was < 0.01%, with androstendione 0.91% and with 5-α-
dihydrotestosterone 1.89%. For validation of between assay precision a pooled 
samples were analyzed 6 times a day for a total of 10 days (n = 60) and for within 
assay precision pooled samples were measured 20 times a day (n = 20). Inter- and 
intraassay coefficients of variation were 2.2% and 1.4%, respectively. 
 
5.5. Statistical analysis 
Data were analyzed using StatView 5.0 software program (SAS Institute, Wangen, 
Switzerland) and tested for normal distribution. A multivariate analysis of variance 
(ANOVA) with repeated measures was carried out to assess the effects of group 
allocation, time of collection and treatment (interaction between group and time) on 
semen characteristics and on plasma testosterone concentrations. Non-normally 
distributed values (acrosome defects, testosterone concentration) were logarithmized 
for this purpose. Group (EquiGen®, control) differences at individual time points were 
compared by unpaired student’s t-test in normally (volume, concentration, daily 
sperm output, total and progressive motility, normal sperm, major defects, nuclear 
vacuoles, abnormal heads) and by Mann-Whitney test in non-normally distributed 
variables. The level of statistical significance was assumed as P < 0.05. 
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6. Results 
6.1. Plasma testosterone 
Results from ANOVA demonstrate that monthly measured plasma testosterone 
concentrations were significantly influenced by group (P = 0.0207) but neither by time 
of blood collection (P = 0.1429) nor by treatment (interaction between group and 
time, P = 0.9568). 
Mean monthly testosterone values of the EquiGen® group (range 0.32-0.89 ng/mL) 
were always higher during the whole experiment compared to control (range 0.26-
0.42 ng/mL) stallions (Fig. 1). A significant (P < 0.05) group difference was only 
present in November. 
 
 
Fig. 1: Mean (± S.E.M.) plasma testosterone concentrations measured monthly in 9 stallions 
with () and 9 stallions without () EquiGen®. *Significant difference between groups (P < 
0.05, Mann-Whitney test). 
 
Plasma testosterone concentrations in response to hCG-stimulation evaluated by 
ANOVA showed a highly significant effect of hCG-application (P < 0.0001) with a 
significant group difference after stimulation (interaction between group and min after 
hCG, P = 0.0011). There was no significant influence by group (P = 0.1932), single 
stimulation (P = 0.4507) and treatment (interaction between group, single stimulation 
and min after hCG, P = 0.9568). 
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Mean plasma testosterone concentrations in response to hCG stimulation performed 
before, and at the end of the treatment period and 2 months later are shown in Fig. 2. 
The stallions showed highly reproducible responses to intravenous injection of hCG, 
with testosterone concentrations increasing to mean values between 6.42-6.54 
ng/mL at 60 min in stallions treated with EquiGen® and between 4.33-4.53 ng/mL in 
control animals. 
 
 
Fig. 2: Mean (± S.E.M.) plasma testosterone concentrations in response to hCG (6000 IU) 
before (c), at the end of the treatment period (U) and 2 months later () in 9 stallions with 
(a) and 9 stallions without (b) EquiGen®. 
 
6.2. Semen quality 
Data of semen characteristics from ejaculates collected before, during and 2 months 
after the treatment analyzed by ANOVA are shown in Table 1. None of the 
parameters measured were significantly (P > 0.05) influenced either by group or by 
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time of collection had a significant (P < 0.05) effect on volume, concentration, daily 
sperm output, normal spermatozoa, acrosome defects and abnormal heads in both 
groups. Changes of mean group values of these parameters during the whole study 
are shown in Fig. 3 and 4. A significant (P < 0.05) group difference in sperm 
concentration was present in September (Fig. 3b). 
 
Tab. 1: Means (± S.E.M.) of semen characteristics from ejaculates collected from 9 stallions 
with and 9 stallions without EquiGen® and the effect of group, time of semen collection and 
interaction between group and time 
 
Parameter EquiGen® 
m ± S.E.M. 
Control 
m ± S.E.M. 
Group
P 
Time 
P 
Interaction 
P 
Volume (mL) 28.9  ±  2.2 24.5  ±12.9 0.4455   0.0115* 0.1909 
Concentration (x 106/mL) 241.8  ±15.4 175.4  ±13.4 0.0907   0.0013* 0.4258 
Daily sperm output (x 109) 5.6  ±  0.3 3.8  ±  0.4 0.0922   0.0165* 0.8587 
Total motility (%) 75.1  ±  1.6 75.1  ±  1.5 0.9979 0.3323 0.9505 
Progressive motility (%) 50.5  ±  2.0 52.2  ±  2.1 0.7976 0.3103 0.9792 
Normal spermatozoa (%) 18.6  ±  2.4 22.2  ±  2.4 0.6687   0.0338* 0.2318 
Major sperm defects (%) 74.8  ±  2.7 70.5  ±  2.5 0.6375 0.0686 0.1007 
Acrosome defects (%) 16.0  ±  2.1 7.6  ±  1.1 0.1481   0.0093* 0.6691 
Nuclear vacuoles (%) 15.0  ±  1.6 17.8  ±  2.6 0.7096 0.0533 0.4929 
Abnormal heads (%) 33.7  ±  2.6 26.1  ±  2.1 0.3307   0.0308* 0.3975 
*Significant (P < 0.05) 
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Fig. 3: Mean (± S.E.M.) volume (a), sperm concentration (b) and daily sperm output (c) in 
ejaculates collected monthly from 9 stallions with () and 9 stallions without () EquiGen® 
*Significant difference between groups (P < 0.05, unpaired student’s t-test) difference 
between groups. 
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Fig. 4: Mean (± S.E.M.) percentage of normal sperm (a), acrosome defects (b) and abnormal 
heads (c) in ejaculates collected monthly from 9 stallions with () and 9 stallions without () 
EquiGen®. 
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6.3. Adverse effects 
Adverse effects were observed in 6 of 9 stallions during the first month of EquiGen® 
treatment. The most prominent reactions were swelling at the injection site, apathy 
and pyrexia. Animals with elevated body temperature above 38.5°C were treated with 
vedaprofen (Quadrisol®, Intervet International BV, The Netherlands) a non steroidal 
anti-inflammatory drug known to have no influence on semen quality (Janett et al., 
2005). 
 
7. Discussion 
Results of our investigation demonstrate that 10 mg recombinant equine 
somatotropin (EquiGen®) administered once daily during 90 days did not significantly 
influence plasma testosterone concentrations or semen quality. A seasonal pattern of 
testosterone secretion, with lowest values during winter, as reported by others (Byers 
et al., 1983; Cox et al., 1988; Clay and Clay, 1992; Inoue et al., 1992; Aurich et al., 
2003) was not seen in our study. A seasonal effect of testosterone was also absent 
after hCG-stimulation, performed in July, October and December. These findings 
may be explained by the short experimental period of only 6 months lasting from 
midsummer (July) until early winter (December) and by the low sampling frequency 
for basal and stimulated testosterone concentrations. Based on episodic testosterone 
secretion in the stallion (Byers et al., 1993; Clay and Clay, 1992) a seasonal pattern 
can not be identified by obtaining only single monthly values. Irrespective of 
treatment, the hCG-induced testosterone release after each stimulation differed not 
significantly. From these results it can be concluded that the daily injections of 
EquiGen® did not improve Leydig cell function either by increasing the cell number or 
their sensitivity for LH. This observation corresponds with the results of Storer et al. 
(2005) who demonstrated that daily intramuscular injections of 20 µg/kg body weight 
(an equivalent dose as used in our experiment) EquiGen® for 21 days in 5 stallions 
increased IGF-I concentrations but did not influence pituitary gonadotrope function or 
testosterone secretion. In contrast to the horse, the use of GH in rodents has been 
shown to stimulate testosterone secretion (Horikawa et al., 1989; Ohyama et al., 
1995]. 
In order to compare daily sperm output and semen quality over time, ejaculates were 
collected using a standardized protocol with depletion of extragonadal sperm 
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reserves during 4 consecutive days followed by 3 further daily collections for 
determination of semen characteristics (Love et al., 1991). During the entire 
experimental period of 6 months, some of the semen characteristics (volume, 
concentration, daily sperm output, normal sperm, acrosome defects, abnormal 
heads) showed significant variations in both groups over time. These differences in 
semen quality may be explained by a seasonal effect as shown in previous studies 
(Janett et al., 2003a; 2003b). An effect on semen quality parameters attributable to 
EquiGen®, however, was not obvious. Storer et al. (2005) also looked at testicular 
function in the stallion, and reported an increased ejaculate volume as the only 
measurable effect after EquiGen® application, with semen being collected every 
other day for 14 days beginning 2 months after initiation of the treatment. This study, 
however, was carried out during the non breeding season and EquiGen® was given 
during 21 days only which makes a comparison with our data difficult. The lack of 
clear somatotropic action on gonadal function in the stallion is difficult to interpret and 
is supported by in vitro experiments showing that equine GH and humane 
recombinant IGF-I had no steroidogenic effect on Leydig cells (Hess and Roser, 
2005). 
In the aged bull, subcutaneous treatment with 640mg recombinant bovine GH every 
two weeks over 14 weeks was shown to have no effect on blood testosterone 
concentration. It did, however, increase sperm motility after freezing-thawing and 
non-return rate after artificial insemination (Sauerwein et al., 2000). The effect on 
sperm motility after freezing may be more attributable to GH induced changes in the 
spermatozoal environment, as a direct influence of GH on spermatogenesis could not 
be show in the bull (Santos et al., 1999). This is in agreement with earlier reports 
where GH supplementation to prepubertal bulls (MacDonald and Deaver, 
1993;Hagen et al., 1991) and boars (Swanlund et al., 1995) did not improve testicular 
development. In the young boar, however, daily treatment with porcine GH from 8 
through 40 days of age promoted tubular and Sertoli cell maturation without any 
detectable change in plasma testosterone concentration (Swanlund et al., 1995). 
From reports in humans (Laron, 1984) and animal models (McDonald and Deaver, 
1993; Ohyama et al., 1995; Swanlund et al., 1995; Breier et al., 1996; Gravance et 
al., 1997) we can conclude that a beneficial effect of somatotropin on male 
Influence of long-term treatment with equine somatotropin (EquiGen®) on 
gonadal function in stallions with poor semen quality 
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reproductive performance is likely to be confined to prepubertal individuals or growth 
hormone deficient patients. 
Adverse effects with reactions including swelling and pain at the injection site as well 
as pyrexia were observed in 6 of 9 stallions given EquiGen® during the first month of 
treatment. To minimize side effects we recommend halving the dose (5mg/day) 
during the first week of treatment and to rotate the daily intramuscular injections 
between at least 4 different injection sites. 
In summary it seems that long-term treatment with EquiGen® did not influence 
plasma testosterone concentrations nor semen quality in clinically healthy adult 
stallions with poor semen quality. 
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